#China #Suzhou #Insilico Medicine #siRNA #Ribo

Ribo and Insilico Medicine Strengthen Ties for Innovative siRNA Solutions

Suzhou Ribo Life Science Co., Ltd. has announced an exciting new chapter in pharmaceutical development by entering into a strategic collaboration with Insilico Medicine. This partnership aims to leverage both companies’ core competencies in small interfering RNA (siRNA) therapies and artificial intelligence to accelerate the drug discovery process and clinical outcomes.

The collaboration underscores a mutual goal among both companies: the identification of therapeutic targets, sophisticated drug design, and optimization of drug candidates. As Ribo and Insilico Medicine combine their innovative capabilities, they seek to tackle unmet clinical needs that have persisted in the medical field, enabling them to introduce new solutions faster and more efficiently.

siRNA drugs enable precise silencing of pathogenic genes leveraging the RNA interference (RNAi) mechanism. These drugs are becoming increasingly important in the third wave of modern pharmaceuticals due to their expansive action spectrum, tailored digital design, and overall higher patient adherence based on their longevity. The integration of AI technology promises to transform the efficiency and success rates of siRNA-based drug development, focusing particularly on targets that conventional methodologies have found challenging.

Ribo's approach to drug development includes a sophisticated AI-driven platform that streamlines the design and intensive computational analysis of siRNA sequences. The company has built a high-efficiency ligand screening system that uses algorithms to rapidly identify and optimize high-quality candidate molecules. Moreover, during clinical phases, AI technologies can predict efficacy and safety outcomes across various patient populations, substantially enhancing the prospects of successful clinical trials.

Previously, Ribo and Insilico Medicine engaged in a cooperative effort focused on autonomous high-throughput screening. This newly enhanced partnership capitalizes on Ribo's extensive industry experience in siRNA technology and drug research while tapping into Insilico’s AI-based drug discovery framework. The synergy between the two organizations promises to expedite innovative siRNA medicines, with an emphasis on addressing critical health challenges across the globe.

Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, expressed enthusiasm upon signing the cooperation agreement, citing the strong communication and trust built between the two companies. He also highlighted Ribo as the first partner utilizing their LifeStar 2 automated laboratory platform for high-throughput experimental services, showcasing its industrial capability. Dr. Ren remarked, “With the continuous innovation of our AI algorithms, recent updates to the Pharma.AI platform pave the way for enhanced collaborations in drug development using oligonucleotides.”

On a similar note, Li-Ming Gan, Global Co-CEO and President of R&D at Ribo, reiterated that the companies share compatible innovations and aspirations across their respective fields. He noted Ribo's rapid growth, emphasizing the importance of technological advancements in expediting their pipeline of drug candidates. Gan stated, “Empowered by Insilico Medicine’s leading Pharma.AI platform, we anticipate even more substantial momentum in our strategic development stage to meet pressing therapeutic needs.”

The collaboration marks a pivotal moment for both organizations, promising not just improved efficiency and accuracy in drug development but also the potential for groundbreaking therapeutic solutions. The long-term projects born from this partnership may materially benefit global health and promote healthier lifestyles for patients awaiting innovative treatments.

About Insilico Medicine

Insilico Medicine is a global pioneer in biotechnology that merges artificial intelligence with automation to revolutionize drug discovery and life sciences. With its proprietary Pharma.AI platform, the company targets unmet medical needs in disease areas including cancer, fibrosis, and metabolic disorders.

Founded in 2025, Insilico began trading on the Hong Kong Stock Exchange under the symbol 03696.HK and continues to expand its AI platform applications into materials science, nutrition, and veterinary medicine.

About Ribo

Suzhou Ribo Life Science Co., Ltd. is dedicated to developing and commercializing siRNA therapies to provide groundbreaking solutions in treating serious medical conditions. Co-listing on the Hong Kong Stock Exchange in January 2026, Ribo is focused on delivering innovative treatments while committing to transformative advancements in the global healthcare landscape.

In conclusion, this collaboration exemplifies the dynamic intersection of technology and pharmaceuticals, highlighting how collective expertise can reshape healthcare.

• ---